Equity Profile

FMS

Fresenius Medical Care AG

Health CareHealth Care Services$13.1B

May5Tue

Pre-Earnings Brief

UpcomingQ1-2026After Close9:00 AM EDT

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.50

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its services.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Fresenius Medical Care AG is a leading provider of products and services for individuals with kidney diseases. Operating in the health care sector, the company focuses on dialysis services and related products, which are essential for patients with chronic kidney failure. With a market cap of $13 billion, its performance is closely tied to trends in health care spending and aging populations.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, slightly missing the estimate of $0.18. The stock reacted negatively, declining by 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Fresenius Medical Care to report an EPS of $0.50 and revenue of $4.6 billion for Q1 2026. The market is looking for signs of recovery after a disappointing last quarter.

Bull Case

If the company beats EPS estimates, it could signal a rebound in demand for its services, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses estimates again, it may raise concerns about its operational efficiency and long-term growth prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.50

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$4.6B

Revenue figures provide insight into the company's sales performance and market demand for its services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A beat on EPS could indicate improved operational performance and restore investor confidence after recent misses.

What are the revenue growth trends in the dialysis segment?

Understanding revenue trends will help gauge demand for Fresenius's services and its ability to capture market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a recovery in demand for dialysis services, particularly as aging populations increase health care needs.

Supporting Evidence

The options market is pricing in a larger move than historical averages suggest, indicating heightened uncertainty.

Fresenius has historically shown resilience in demand during economic downturns, which may not be fully reflected in current estimates.

Key Risk

If revenue growth in the dialysis segment shows unexpected strength, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether Fresenius can overcome recent operational hurdles and regain market trust.

Bull Confirmed If

An EPS of $0.53 or higher would confirm strong operational recovery and investor confidence.

Bear Confirmed If

An EPS below $0.47 would suggest ongoing challenges in the business and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move of about 4.4%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests a potential stock increase of around 0.54% on the following day, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary on future growth.

Miss

If the company misses EPS estimates again, history suggests a potential decline of about 1.23%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on demand trends in the dialysis segment.
2Management's commentary on cost control measures and operational efficiency.
3Insights into competitive positioning and market share.
4Guidance on future revenue expectations and growth strategies.
5Any developments regarding regulatory changes impacting the health care sector.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

May4

GRABReported

Grab Holdings Limited

RecapView

May4

GBDCReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

$0.50

Revenue

Revenue figures provide insight into the company's sales performance and market demand for its services.

$4.6B

Wall Street expectations, options signals, track record, and call prep available with Pro.

FMS Q1-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

25%

Avg EPS Surprise

-6.74%

Avg Stock Reaction

-1.23%

Last Quarter Recap

In Q1 2023, Fresenius Medical Care reported an EPS of $0.17, slightly missing the estimate of $0.18. The stock reacted negatively, declining by 0.09% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Fresenius Medical Care to report an EPS of $0.50 and revenue of $4.6 billion for Q1 2026. The market is looking for signs of recovery after a disappointing last quarter.

Bull Case

If the company beats EPS estimates, it could signal a rebound in demand for its services, potentially leading to a positive stock reaction.

Bear Case

Conversely, if the company misses estimates again, it may raise concerns about its operational efficiency and long-term growth prospects.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.50

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

Revenue

$4.6B

Revenue figures provide insight into the company's sales performance and market demand for its services.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS exceed the consensus estimate of $0.50?

A beat on EPS could indicate improved operational performance and restore investor confidence after recent misses.

What are the revenue growth trends in the dialysis segment?

Understanding revenue trends will help gauge demand for Fresenius's services and its ability to capture market share.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for a recovery in demand for dialysis services, particularly as aging populations increase health care needs.

Supporting Evidence

The options market is pricing in a larger move than historical averages suggest, indicating heightened uncertainty.

Fresenius has historically shown resilience in demand during economic downturns, which may not be fully reflected in current estimates.

Key Risk

If revenue growth in the dialysis segment shows unexpected strength, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will be critical in determining whether Fresenius can overcome recent operational hurdles and regain market trust.

Bull Confirmed If

An EPS of $0.53 or higher would confirm strong operational recovery and investor confidence.

Bear Confirmed If

An EPS below $0.47 would suggest ongoing challenges in the business and could lead to further stock declines.

Pre-Earnings Positioning

Options Market

Implied Move

±4.4%

Historical Avg

±2.7%

Pricing rich

The options market is pricing in a significant move of about 4.4%, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±4.4% while FMS has averaged ±2.7% over the last 8 prints — setup is pricing rich.

Detail

30d HV

22.1%

Calls (300)P/C Ratio: 1.00Puts (0)

Edge

Institutional Ownership

Smart-money positioning from the most recent 13F filings.

Top holders trimming

Institutional

8.64%

of float

Insider

0.00%

of float

Holders

255

institutions

Top Holders· as of Dec 2025

Pzena Investment Management LLC
14,752,836 sh · $335.9M
2.64%
-0.4%

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Fresenius beats expectations, history suggests a potential stock increase of around 0.54% on the following day, confirming a positive turnaround.

In-Line / Cautious

If results are in line with expectations, the stock may see muted movement as investors await further commentary on future growth.

Miss

If the company misses EPS estimates again, history suggests a potential decline of about 1.23%, raising concerns about its growth trajectory.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on demand trends in the dialysis segment.
2Management's commentary on cost control measures and operational efficiency.
3Insights into competitive positioning and market share.
4Guidance on future revenue expectations and growth strategies.
5Any developments regarding regulatory changes impacting the health care sector.